The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery

G.M. Bokkerink; E. J. de Graaf; C.J. Punt; I.D. Nagtegaal; H.J.T. Rutten; J.J. Nuyttens; E. van Meerten; P.G. Doornebosch; P.J. Tanis; E.J. Derksen; R.S. Dwarkasing; C.A. Marijnen; A. Cats; R.A. Tollenaar; I.H. de Hingh; H.J. Rutten; G.P. van der Schelling; A.J. Ten Tije; J.W. Leijtens; G. Lammering; G.L. Beets; T.J. Aufenacker; A. Pronk; E.R. Manusama; C. Hoff; A.J. Bremers; C. Verhoef; J.H. de Wilt

doi:10.1186/1471-2482-11-34

The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery

G.M. Bokkerink^*
, E. J. de Graaf
, C.J. Punt
, I.D. Nagtegaal
, H.J.T. Rutten
, J.J. Nuyttens
, E. van Meerten
, P.G. Doornebosch
, P.J. Tanis
, E.J. Derksen
, R.S. Dwarkasing
, C.A. Marijnen
, A. Cats
, R.A. Tollenaar
, I.H. de Hingh
, H.J. Rutten
, G.P. van der Schelling
, A.J. Ten Tije
, J.W. Leijtens
, G. Lammering

G.L. Beets, T.J. Aufenacker, A. Pronk, E.R. Manusama, C. Hoff, A.J. Bremers, C. Verhoef, J.H. de Wilt

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

ABSTRACT: Background The CARTS study is a multicenter feasibility study, investigating the role of rectum saving surgery for distal rectal cancer. Methods/Design Patients with a clinical T1-3 N0 M0 rectal adenocarcinoma below 10 cm from the anal verge will receive neoadjuvant chemoradiation therapy (25 fractions of 2 Gy with concurrent capecitabine). Transanal Endoscopic Microsurgery (TEM) will be performed 8 - 10 weeks after the end of the preoperative treatment depending on the clinical response. Primary objective is to determine the number of patients with a (near) complete pathological response after chemoradiation therapy and TEM. Secondary objectives are the local recurrence rate and quality of life after this combined therapeutic modality. A three-step analysis will be performed after 20, 33 and 55 patients to ensure the feasibility of this treatment protocol. DISCUSSION: The CARTS-study is one of the first prospective multicentre trials to investigate the role of a rectum saving treatment modality using chemoradiation therapy and local excision. The CARTS study is registered at clinicaltrials.gov (NCT01273051).

Original language	English
Pages (from-to)	34
Journal	BMC Surgery
Volume	11
Issue number	1
DOIs	https://doi.org/10.1186/1471-2482-11-34
Publication status	Published - 1 Jan 2011

Access to Document

10.1186/1471-2482-11-34Licence: CC BY

http://www.ncbi.nlm.nih.gov/pubmed/22171697

Cite this

Bokkerink, G. M., de Graaf, E. J., Punt, C. J., Nagtegaal, I. D., Rutten, H. J. T., Nuyttens, J. J., van Meerten, E., Doornebosch, P. G., Tanis, P. J., Derksen, E. J., Dwarkasing, R. S., Marijnen, C. A., Cats, A., Tollenaar, R. A., de Hingh, I. H., Rutten, H. J., van der Schelling, G. P., Ten Tije, A. J., Leijtens, J. W., ... de Wilt, J. H. (2011). The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery. BMC Surgery, 11(1), 34. https://doi.org/10.1186/1471-2482-11-34

@article{f76fc67423624cbabde01337a03f90c4,

title = "The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery",

abstract = "ABSTRACT: Background The CARTS study is a multicenter feasibility study, investigating the role of rectum saving surgery for distal rectal cancer. Methods/Design Patients with a clinical T1-3 N0 M0 rectal adenocarcinoma below 10 cm from the anal verge will receive neoadjuvant chemoradiation therapy (25 fractions of 2 Gy with concurrent capecitabine). Transanal Endoscopic Microsurgery (TEM) will be performed 8 - 10 weeks after the end of the preoperative treatment depending on the clinical response. Primary objective is to determine the number of patients with a (near) complete pathological response after chemoradiation therapy and TEM. Secondary objectives are the local recurrence rate and quality of life after this combined therapeutic modality. A three-step analysis will be performed after 20, 33 and 55 patients to ensure the feasibility of this treatment protocol. DISCUSSION: The CARTS-study is one of the first prospective multicentre trials to investigate the role of a rectum saving treatment modality using chemoradiation therapy and local excision. The CARTS study is registered at clinicaltrials.gov (NCT01273051).",

author = "G.M. Bokkerink and \{de Graaf\}, \{E. J.\} and C.J. Punt and I.D. Nagtegaal and H.J.T. Rutten and J.J. Nuyttens and \{van Meerten\}, E. and P.G. Doornebosch and P.J. Tanis and E.J. Derksen and R.S. Dwarkasing and C.A. Marijnen and A. Cats and R.A. Tollenaar and \{de Hingh\}, I.H. and H.J. Rutten and \{van der Schelling\}, G.P. and \{Ten Tije\}, A.J. and J.W. Leijtens and G. Lammering and G.L. Beets and T.J. Aufenacker and A. Pronk and E.R. Manusama and C. Hoff and A.J. Bremers and C. Verhoef and \{de Wilt\}, J.H.",

year = "2011",

month = jan,

day = "1",

doi = "10.1186/1471-2482-11-34",

language = "English",

volume = "11",

pages = "34",

journal = "BMC Surgery",

issn = "1471-2482",

publisher = "BioMed Central Ltd",

number = "1",

}

Bokkerink, GM, de Graaf, EJ, Punt, CJ, Nagtegaal, ID, Rutten, HJT, Nuyttens, JJ, van Meerten, E, Doornebosch, PG, Tanis, PJ, Derksen, EJ, Dwarkasing, RS, Marijnen, CA, Cats, A, Tollenaar, RA, de Hingh, IH, Rutten, HJ, van der Schelling, GP, Ten Tije, AJ, Leijtens, JW, Lammering, G, Beets, GL, Aufenacker, TJ, Pronk, A, Manusama, ER, Hoff, C, Bremers, AJ, Verhoef, C & de Wilt, JH 2011, 'The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery', BMC Surgery, vol. 11, no. 1, pp. 34. https://doi.org/10.1186/1471-2482-11-34

TY - JOUR

T1 - The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery

AU - Bokkerink, G.M.

AU - de Graaf, E. J.

AU - Punt, C.J.

AU - Nagtegaal, I.D.

AU - Rutten, H.J.T.

AU - Nuyttens, J.J.

AU - van Meerten, E.

AU - Doornebosch, P.G.

AU - Tanis, P.J.

AU - Derksen, E.J.

AU - Dwarkasing, R.S.

AU - Marijnen, C.A.

AU - Cats, A.

AU - Tollenaar, R.A.

AU - de Hingh, I.H.

AU - Rutten, H.J.

AU - van der Schelling, G.P.

AU - Ten Tije, A.J.

AU - Leijtens, J.W.

AU - Lammering, G.

AU - Beets, G.L.

AU - Aufenacker, T.J.

AU - Pronk, A.

AU - Manusama, E.R.

AU - Hoff, C.

AU - Bremers, A.J.

AU - Verhoef, C.

AU - de Wilt, J.H.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - ABSTRACT: Background The CARTS study is a multicenter feasibility study, investigating the role of rectum saving surgery for distal rectal cancer. Methods/Design Patients with a clinical T1-3 N0 M0 rectal adenocarcinoma below 10 cm from the anal verge will receive neoadjuvant chemoradiation therapy (25 fractions of 2 Gy with concurrent capecitabine). Transanal Endoscopic Microsurgery (TEM) will be performed 8 - 10 weeks after the end of the preoperative treatment depending on the clinical response. Primary objective is to determine the number of patients with a (near) complete pathological response after chemoradiation therapy and TEM. Secondary objectives are the local recurrence rate and quality of life after this combined therapeutic modality. A three-step analysis will be performed after 20, 33 and 55 patients to ensure the feasibility of this treatment protocol. DISCUSSION: The CARTS-study is one of the first prospective multicentre trials to investigate the role of a rectum saving treatment modality using chemoradiation therapy and local excision. The CARTS study is registered at clinicaltrials.gov (NCT01273051).

AB - ABSTRACT: Background The CARTS study is a multicenter feasibility study, investigating the role of rectum saving surgery for distal rectal cancer. Methods/Design Patients with a clinical T1-3 N0 M0 rectal adenocarcinoma below 10 cm from the anal verge will receive neoadjuvant chemoradiation therapy (25 fractions of 2 Gy with concurrent capecitabine). Transanal Endoscopic Microsurgery (TEM) will be performed 8 - 10 weeks after the end of the preoperative treatment depending on the clinical response. Primary objective is to determine the number of patients with a (near) complete pathological response after chemoradiation therapy and TEM. Secondary objectives are the local recurrence rate and quality of life after this combined therapeutic modality. A three-step analysis will be performed after 20, 33 and 55 patients to ensure the feasibility of this treatment protocol. DISCUSSION: The CARTS-study is one of the first prospective multicentre trials to investigate the role of a rectum saving treatment modality using chemoradiation therapy and local excision. The CARTS study is registered at clinicaltrials.gov (NCT01273051).

U2 - 10.1186/1471-2482-11-34

DO - 10.1186/1471-2482-11-34

M3 - Article

C2 - 22171697

SN - 1471-2482

VL - 11

SP - 34

JO - BMC Surgery

JF - BMC Surgery

IS - 1

ER -

The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery

Abstract

Access to Document

Fingerprint

Cite this